Bayer, Evotec partner to boost precision medicine for cardiology
Bayer and Evotec are expanding their collaboration to develop innovative therapies in precision cardiology, and the strategic alliance…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 May 24
Bayer and Evotec are expanding their collaboration to develop innovative therapies in precision cardiology, and the strategic alliance…
01 May 24
The positive top-line results revealed that the Phase 2/3 trial achieved its primary endpoint of improvement on the…
01 May 24
Lupkynis’ updated label no longer includes the disclaimer regarding its safety and efficacy beyond one year and incorporates…
01 May 24
The partnership, spread across various therapeutic fields, aims to assess the use of polygenic risk scores in improving…
30 Apr 24
ONO will merge Deciphera with and into its fully owned subsidiary, with Deciphera as the surviving entity, which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Apr 24
The full approval is based on positive results from global Phase 3 innovaTV 301 study that showed overall…
30 Apr 24
Enhertu demonstrated a statistically significant and clinically meaningful improvement in PFS against standard-of-care chemotherapy in the primary trial…
30 Apr 24
The approval was based on the findings from the 4WHIM Phase 3 clinical trial in which treatment with…
30 Apr 24
RescEU is part of the EU Civil Protection Mechanism, established by the European Commission as a safety net…
30 Apr 24
This collaboration underscores Merck KGaA, Darmstadt, Germany and Huma's joint commitment to advancing patient-directed care and empowering patients…